Given that the disease mechanisms behind COPA syndrome skew T-cells toward the Th17 phenotype, mTOR inhibitors could be beneficial, with current evidence being scarce but promising [48]. The gene discussed is MTOR; the disease is autoimmune interstitial lung disease-arthritis syndrome.